MsbA: an ABC transporter paradigm

Author(s):  
Christian Bonifer ◽  
Clemens Glaubitz

ATP-binding cassette (ABC) transporters play an important role in various cellular processes. They display a similar architecture and share a mechanism which couples ATP hydrolysis to substrate transport. However, in the light of current data and recent experimental progress, this protein superfamily appears as multifaceted as their broad substrate range. Among the prokaryotic ABC transporters, MsbA can serve as a paradigm for research in this field. It is located in the inner membrane of Gram-negative bacteria and functions as a floppase for the lipopolysaccharide (LPS) precursor core-LPS, which is involved in the biogenesis of the bacterial outer membrane. While MsbA shows high similarity to eukaryotic ABC transporters, its expression in Gram-negative bacteria makes it conveniently accessible for many experimental approaches from spectroscopy to 3D structure determination. As an essential protein for bacterial membrane integrity, MsbA has also become an attractive target for the development of novel antibiotics. Furthermore, it serves as a model for multidrug efflux pumps. Here we provide an overview of recent findings and their relevance to the field, highlight the potential of methods such as solid-state NMR and EPR spectroscopy and provide a perspective for future work.

2018 ◽  
Vol 169 (7-8) ◽  
pp. 351-356 ◽  
Author(s):  
Helen I. Zgurskaya ◽  
Valentin V. Rybenkov ◽  
Ganesh Krishnamoorthy ◽  
Inga V. Leus

2020 ◽  
Vol 64 (11) ◽  
Author(s):  
Burcu Isler ◽  
Timothy J. Kidd ◽  
Adam G. Stewart ◽  
Patrick Harris ◽  
David L. Paterson

ABSTRACT Achromobacter is a genus of nonfermenting Gram-negative bacteria under order Burkholderiales. Although primarily isolated from respiratory tract of people with cystic fibrosis, Achromobacter spp. can cause a broad range of infections in hosts with other underlying conditions. Their rare occurrence and ever-changing taxonomy hinder defining their clinical features, risk factors for acquisition and adverse outcomes, and optimal treatment. Achromobacter spp. are intrinsically resistant to several antibiotics (e.g., most cephalosporins, aztreonam, and aminoglycosides), and are increasingly acquiring resistance to carbapenems. Carbapenem resistance is mainly caused by multidrug efflux pumps and metallo-β-lactamases, which are not expected to be overcome by new β-lactamase inhibitors. Among the other new antibiotics, cefiderocol, and eravacycline were used as salvage therapy for a limited number of patients with Achromobacter infections. In this article, we aim to give an overview of the antimicrobial resistance in Achromobacter species, highlighting the possible place of new antibiotics in their treatment.


2014 ◽  
Vol 9 (10) ◽  
pp. 1165-1177 ◽  
Author(s):  
Jessica MA Blair ◽  
Grace E Richmond ◽  
Laura JV Piddock

Author(s):  
Maria Aparecida Scatamburlo Moreira ◽  
Edmar Chartone de Souza ◽  
Célia Alencar de Moraes

Sign in / Sign up

Export Citation Format

Share Document